What are the recommended inpatient orders, including empiric antibiotic regimen and supportive care, for an adult with community-acquired pneumonia?

Inpatient Orders for Community-Acquired Pneumonia

Empiric Antibiotic Regimen

For hospitalized adults with community-acquired pneumonia on a general medical ward (non-ICU), initiate either a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) OR a β-lactam plus macrolide combination (ceftriaxone 1-2 g IV daily or cefotaxime 1-2 g IV every 8 hours PLUS azithromycin 500 mg IV daily). 1, 2

Non-ICU Inpatients

The 2007 IDSA/ATS guidelines provide strong, level I evidence for both treatment approaches 1:

• Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg IV daily OR moxifloxacin 400 mg IV daily
• β-lactam + macrolide combination:
  • Preferred β-lactams: Ceftriaxone 1-2 g IV daily, cefotaxime 1-2 g IV every 8 hours, or ampicillin-sulbactam 1.5-3 g IV every 6 hours
  • Plus azithromycin 500 mg IV daily OR clarithromycin 500 mg IV twice daily
  • Doxycycline can substitute for the macrolide (level III evidence)

For penicillin-allergic patients, use a respiratory fluoroquinolone 1.

ICU Patients (Severe CAP)

For patients requiring ICU admission, use combination therapy with a β-lactam (ceftriaxone 1-2 g IV daily, cefotaxime 1-2 g IV every 8 hours, or ampicillin-sulbactam 1.5-3 g IV every 6 hours) PLUS either azithromycin 500 mg IV daily OR a respiratory fluoroquinolone. 1, 2

Special Considerations for ICU Patients:

If Pseudomonas risk factors present (structural lung disease like bronchiectasis, recent antibiotics, recent hospitalization):

• Use antipseudomonal β-lactam: piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, imipenem 500 mg IV every 6 hours, or meropenem 1 g IV every 8 hours
• PLUS ciprofloxacin 400 mg IV every 8 hours OR levofloxacin 750 mg IV daily
• OR antipseudomonal β-lactam PLUS aminoglycoside (gentamicin 5-7 mg/kg IV daily or tobramycin 5-7 mg/kg IV daily) PLUS azithromycin or respiratory fluoroquinolone 1, 2

If MRSA risk factors present (prior IV antibiotics within 90 days, hospitalization in unit where >20% S. aureus isolates are methicillin-resistant, high mortality risk):

• Add vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600 mg IV every 12 hours 1, 2

Supportive Care Orders

Initial Assessment and Monitoring

Obtain chest radiograph to confirm diagnosis 3. Order the following laboratory tests:

• Complete blood count with differential
• Basic metabolic panel (creatinine, BUN, glucose, electrolytes)
• Liver function tests
• Oxygen saturation assessment
• Two sets of blood cultures prior to antibiotic administration 3

Oxygen and Respiratory Support

• Supplemental oxygen to maintain SpO₂ ≥90%
• Consider noninvasive ventilation for patients with hypoxemia or respiratory distress who don't require immediate intubation 1

Fluid Management

• Intravenous fluids for hemodynamic support as needed
• For patients with persistent septic shock despite adequate fluid resuscitation, consider vasopressor support 1

Additional Supportive Measures

For severe CAP with septic shock: Consider drotrecogin alfa activated within 24 hours of admission (weak recommendation, level II evidence) 1

Screen hypotensive, fluid-resuscitated patients for occult adrenal insufficiency 1

Timing of Antibiotic Administration

Administer the first antibiotic dose while the patient is still in the emergency department (moderate recommendation, level III evidence) 1. Do not delay antibiotics for diagnostic testing.

Transition to Oral Therapy

Switch from IV to oral antibiotics when the patient is:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Has normally functioning gastrointestinal tract 1

This typically occurs within 2-3 days for most patients with non-severe CAP 4. Use the same antibiotic class when switching (e.g., IV levofloxacin to oral levofloxacin).

Duration of Therapy

Treat for a minimum of 5 days, ensure the patient is afebrile for 48-72 hours, and has no more than 1 sign of clinical instability before discontinuing therapy 1. Most patients with uncomplicated CAP do not require more than 5-8 days of total antibiotic therapy 5, 1.

Infection Control

During influenza season, test for influenza using rapid nucleic acid amplification tests 2. If positive, initiate oseltamivir and continue antibacterial therapy as influenza increases risk of secondary bacterial pneumonia 1.

Common Pitfalls to Avoid

• Do not use macrolide monotherapy for hospitalized patients - resistance rates make this inadequate 1
• Do not routinely add MRSA or Pseudomonas coverage without risk factors - this leads to unnecessary broad-spectrum antibiotic use 2
• Do not continue IV antibiotics beyond clinical stability - early transition to oral therapy is safe and reduces complications 1
• Do not extend antibiotic duration beyond 5-8 days in uncomplicated cases - longer courses increase adverse effects without benefit 5, 1, 6

Discharge Planning

Prior to discharge, ensure patients receive:

• Pneumococcal vaccination (if eligible and not previously vaccinated)
• Influenza vaccination (if during flu season)
• Tobacco cessation counseling (if applicable) 4